Skip to main content

Table 2 Univariate and multivariate analysis of AML patients for overall survival

From: Low expression of ACLY associates with favorable prognosis in acute myeloid leukemia

Variables Univariate analysis Multivariate analysis
P value HR (95% CI) P value HR (95% CI)
ACLY expression (high vs. low) 0.001 2.19 (1.38, 3.475) 0.029 1.805 (1.062, 3.068)
Age < 0.001 1.007 (1.004, 1.011) 0.009 1.006 (1.001, 1.01)
WBC < 0.001 1.005 (1.003, 1.007) < 0.001 1.004 (1.002, 1.006)
Cytogenetic risks
 Intermediate vs. favorable 0.003 3.811 (1.556, 9.337) 0.027 3.748 (1.164, 12.069)
 Poor vs. favorable < 0.001 8.539 (3.247, 22.454) 0.001 7.978 (2.34, 27.197)
Gene mutations (mutation vs. wild-type)
 FLT3-ITD 0.022 1.66(1.076, 2.56) 0.007 1.969(1.208,3.21)
 NPM1 0.051 1.434(0.998,2.061) 0.812 1.05(0.702,1.571)
 CEBPADM 0.022 0.385(0.169,0.874) 0.040 0.409(0.175,0.960)
 DNMT3A 0.001 2.474(1.483,4.125) 0.022 1.98(1.105,3.546)
Treatmenta     
 HAA vs. DA 0.001 0.503 (0.335, 0.756) 0.007 0.536 (0.341, 0.842)
 IA vs. DA 0.003 0.567 (0.391, 0.824) 0.002 0.48 (0.304, 0.756)
  1. Age and WBC are taken as continuous variables
  2. WBC white blood cell, DM double-allele, CI confidence intervals, HR hazard ratio
  3. aThe treatment protocols are available from Table 1